NPPA Fixes Retail Price Of 41 Formulations; Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the price of 41 formulations, including those used to treat heart attacks, hypertension, infections, allergies, type 2 diabetes, depression, and anxiety.These include Macleod's Telmisartan and Hydrochlorothiazidel combination (MACSART H...
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the price of 41 formulations, including those used to treat heart attacks, hypertension, infections, allergies, type 2 diabetes, depression, and anxiety.
These include Macleod's Telmisartan and Hydrochlorothiazidel combination (MACSART H 80 & TELMIDUCE H 80), Telmisartan and Amlodipine combination (MACSART AM 80 & TELMIDUCE AM 80), Metformin and Gliclazide combination (MEFOMIN-GZ 60) among others.
In addition to this, the list also includes Akums, Mylan's Cefixime and Ofloxacin combination, Synokem, Cipla's Azelnidipine plus Telmisartan combination, Synokem or Aristo's Atorvastatin plus Clopidogrel plus Aspirin combination capsule.
This comes after in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA), fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No . | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1. | Telmisartan + Amlodipine + Hydrochlorothiazide Tablet | Each film coated tablet contains: Telmisartan IP 40mg, Amlodipine Besylate IP eq. to Amlodipine 5mg Hydrochlorothiazide IP 12.5mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd. | 9.02 |
2. | Dexamethasone +Chloramphenicol Eye Drops | Each ml contains: Dexamethasone Sodium Phosphate IP eq. to Dexamethasone 0.1%w/v, Chloramphenicol IP 1% w/v, | 1 ML | M/s Skymap Healthcare Pvt. Ltd. / M/s Albert David Limited | 4.09 |
3. | Dexamethasone +Chloramphenicol Eye Drops | Each ml contains: Dexamethasone Sodium Phosphate IP eq. to Dexamethasone 0.1%w/v, Chloramphenicol IP 1% w/v, | 1 ML | M/s Skymap Healthcare Pvt. Ltd. | 4.09 |
4. | Telmisartan & Metoprolol Succinate (ER) Tablet | Each uncoated bilayered tablet contains: Telmisartan IP 40mg, Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (As Extended Release form) | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd. | 11.22 |
5. | Telmisartan & Metoprolol Succinate (ER) Tablet | Each uncoated bilayered tablet contains: Telmisartan IP 40mg, Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (As Extended Release form) | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. | 11.22 |
6. | Telmisartan, Amlodipine & Hydrochlorothiazide Tablet | Each film coated tablet contains: Telmisartan IP 40mg, Amlodipine Besylate IP eq. to Amlodipine 5mg, Hydrochlorothiazide IP 12.50 mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. | 9.02 |
Sl. No . | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
7. | Paracetamol, Phenylephrine Hydrochloride , Caffeine & Diphenhydramine Tablet | Each film coated tablet contains: Paracetamol IP 500mg, Phenylephrine Hydrochloride IP 5mg, Caffeine (Anhydrous) IP 30mg Diphenhydramine Hydrochloride IP 25mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 2.99 |
8. | Telmisartan + Cilnidipine + Metoprolol (ER) Tablet | Each film coated Bilayered tablet contains: Telmisartan IP 40mg, Cilnidipine IP 10mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as extended release) 25mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Glenmark Pharmaceuticals Ltd. | 10.16 |
9. | Telmisartan + Cilnidipine + Metoprolol (ER) Tablet | Each film coated Bilayered tablet contains: Telmisartan IP 40mg, Cilnidipine IP 10mg Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate (as extended release) 50mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Glenmark Pharmaceuticals Ltd. | 12.41 |
10. | Telmisartan + Hydrochlorothiazidel Tablet (MACSART H 80 & TELMIDUCE H 80) | Each uncoated bilayered tablet contains: Telmisartan IP 80mg, Hydrochlorothiazide IP 12.50mg | 1 Tablet | M/s Macleods Pharmaceuticals Ltd. | 14.00 |
11. | Telmisartan + Amlodipine Tablet (MACSART AM 80 & TELMIDUCE AM 80) | Each uncoated bilayered tablet contains: Telmisartan IP 80mg, Amlodipine Besylate IP eq. to Amlodipine 5mg | 1 Tablet | M/s Macleods Pharmaceuticals Ltd. | 12.50 |
12. | Metformin + Gliclazide Tablet (MEFOMIN-GZ 60) | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (as Extended Release form), Gliclazide IP 60mg (as Extended Release form), | 1 Tablet | M/s Macleods Pharmaceuticals Ltd. | 9.74 |
13. | Telmisartan + Cilnidipine + Metoprolol (ER) Tablet (NEXOVAS TM 25) | Each film coated Bilayered tablet contains: Telmisartan IP 40mg, Cilnidipine IP 10mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as extended release) 25mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 10.16 |
14. | Atorvastatin + Clopidogrel + Aspirin Capsule | Each Hard gelatine capsule contains: Atorvastatin calcium IP eq. to Atorvastatin 10mg (As Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets), Aspirin IP 75mg (As enteric coated pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd. / M/s Aristo Pharmaceuticals Private Limited. | 4.16 |
Sl. No . | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
15. | Atorvastatin + Clopidogrel + Aspirin Capsule | Each Hard gelatine capsule contains: Atorvastatin calcium IP eq. to Atorvastatin 20mg (As Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets), Aspirin IP 75mg (As enteric coated pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd. / M/s Aristo Pharmaceuticals Private Limited. | 5.61 |
16. | Cefixime & Ofloxacin Tablet | Each film coated tablet contains: Cefixime IP as Trihydrate eq. to Anhydrous Cefixime 200mg Ofloxacin IP 200mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. /M/s Mylan Pharmaceuticals Private Limited. | 11.47 |
17. | Azelnidipine + Telmisartan Tablets | Each film coated bi-layered tablet contains: Azelnidipine IP 8mg, Telmisartan IP 40mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Limited. | 11.02 |
18. | Azelnidipine + Telmisartan Tablets | Each film coated bi-layered tablet contains: Azelnidipine IP 8mg, Telmisartan IP 80mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Cipla Limited. | 13.22 |
19. | Glimepiride + Metformin Hydrochloride prolonged release tablets | Each uncoated bi-layered tablet contains: Glimepiride IP 4mg Metformin Hydrochloride IP 500mg (In prolonged release form) | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 10.25 |
20. | Glimepiride + Metformin Hydrochloride prolonged release tablets | Each uncoated bi-layered tablet contains: Glimepiride IP 4mg Metformin Hydrochloride IP 1000mg (In prolonged release form) | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 9.76 |
21. | Glimepiride + Metformin Hydrochloride prolonged release tablets | Each uncoated bi-layered tablet contains: Glimepiride IP 3mg Metformin Hydrochloride IP 500mg (In prolonged release form) | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 8.41 |
22. | Glimepiride + Metformin Hydrochloride prolonged release tablets | Each uncoated bi-layered tablet contains: Glimepiride IP 3mg Metformin Hydrochloride IP 1000mg (In prolonged release form) | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. | 9.35 |
23. | Telmisartan + Cilnidipine + Metoprolol Tablet (NEXOVAS TM 50) | Each film coated Bilayered tablet contains: Telmisartan IP 40mg, Cilnidipine IP 10mg Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate (as extended release) 50mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 12.41 |
24. | Glimepiride + Metformin | Each uncoated bi-layered tablet contains: | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. | 9.76 |
Sl. No . | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Hydrochloride prolonged release tablets | Glimepiride IP 4mg Metformin Hydrochloride IP 1000mg (In prolonged release form) | Ltd. / M/s Jagsonpal Pharmaceuticals Ltd. | |||
25. | Glimepiride + Metformin Hydrochloride prolonged release tablets | Each uncoated bi-layered tablet contains: Glimepiride IP 4mg Metformin Hydrochloride IP 500mg (In prolonged release form) | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd. | 10.25 |
26. | Glimepiride + Metformin Hydrochloride prolonged release tablets | Each uncoated bi-layered tablet contains: Glimepiride IP 3mg Metformin Hydrochloride IP 500mg (In prolonged release form) | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd. | 8.41 |
27. | Glimepiride + Metformin Hydrochloride prolonged release tablets | Each uncoated bi-layered tablet contains: Glimepiride IP 3mg Metformin Hydrochloride IP 1000mg (In prolonged release form) | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd. | 9.35 |
28. | Escitalopram Oxalate + Clonazepam Tablets IP | Each film coated tablet contains: Escitalopram Oxalate IP Eq. to Escitalopram 5mg, Clonazepam IP 0.25mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Aristo Pharmaceuticals Private Limited. | 6.73 |
29. | Escitalopram Oxalate + Clonazepam Tablets IP | Each film coated tablet contains: Escitalopram Oxalate IP Eq. to Escitalopram 5mg, Clonazepam IP 0.5mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Aristo Pharmaceuticals Private Limited. | 7.40 |
30. | Escitalopram Oxalate + Clonazepam Tablets IP | Each film coated tablet contains: Escitalopram Oxalate IP Eq. to Escitalopram 10mg, Clonazepam IP 0.25mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Aristo Pharmaceuticals Private Limited. | 8.93 |
31. | Escitalopram Oxalate + Clonazepam Tablets IP | Each film coated tablet contains: Escitalopram Oxalate IP Eq. to Escitalopram 10mg, Clonazepam IP 0.5mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Aristo Pharmaceuticals Private Limited. | 10.79 |
32. | Ceftriaxone & Tazobactam for Injection 1125mg | Each vial contains: Ceftiraxone Sodium IP (Sterile) eq. to Ceftriaxone 1g Tazobactam Sodium (Sterile) eq. to Tazobactam 125mg | Each Pack | M/s Nitin Lifesciences Limited / M/s Mylan Pharmaceticals Private Limited | 146.32 |
33. | Moxifloxacin 0.5% w/v + Dexamethasone Phosphate 0.1% w/v Ophthalmic Solution | Each ml contains: Moxifloxacin Hydrochloride IP eq. to Moxifloxacin 5.0mg Dexamethasone Sodium Phosphate IP eq. to Dexamethasone Phosphate 1.0mg Water for Injections IP q. s. to 1ml | 1 ML | M/s Micro Labs Limited | 19.10 |
Sl. No . | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
34. | Metformin Hydrochloride prolonged release + Glimepiride tablet IP | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP (in prolonged release form) 500mg Glimepiride IP 1mg | 1 Tablet | M/s Inventia Healthcare Limited | 5.95 |
35. | Metformin Hydrochloride prolonged release + Glimepiride tablet IP | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP (in prolonged release form) 500mg Glimepiride IP 2mg | 1 Tablet | M/s Inventia Healthcare Limited | 7.73 |
36. | Metformin Hydrochloride prolonged release + Glimepiride tablet IP | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP (in prolonged release form) 1000mg Glimepiride IP 1mg | 1 Tablet | M/s Inventia Healthcare Limited | 6.55 |
37. | Metformin Hydrochloride prolonged release + Glimepiride tablet IP | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP (in prolonged release form) 1000mg Glimepiride IP 2mg | 1 Tablet | M/s Inventia Healthcare Limited | 8.33 |
38. | Norethisterone Acetate Controlled release Tablets | Each film coated controlled release tablet Contains: Norethisterone Acetate BP 10 mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Mankind Pharma Limited | 15.09 |
39. | Norethisterone Acetate Controlled release Tablets | Each film coated controlled release tablet Contains: Norethisterone Acetate BP 15 mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Mankind Pharma Limited | 18.00 |
40. | Metformin Hydrochloride (SR) + Vildagliptin Tablet (VILDAMAC M SR 50/500) | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 500mg (As sustained release form) Vildagliptin 50mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 6.86 |
41. | Metformin Hydrochloride (SR) + Vildagliptin Tablet (VILDAMAC M SR 50/1000) | Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 1000mg (As sustained release form) Vildagliptin 50mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Macleods Pharmaceuticals Ltd. | 7.51 |
The notification further added;
(a) The manufacturer of the above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd